FR11C0035I2 - AQUEOUS SUSPENSIONS OF 9-HYDROXYRISPERIDONE FATTY ACID ESTERS - Google Patents

AQUEOUS SUSPENSIONS OF 9-HYDROXYRISPERIDONE FATTY ACID ESTERS

Info

Publication number
FR11C0035I2
FR11C0035I2 FR11C0035C FR11C0035C FR11C0035I2 FR 11C0035 I2 FR11C0035 I2 FR 11C0035I2 FR 11C0035 C FR11C0035 C FR 11C0035C FR 11C0035 C FR11C0035 C FR 11C0035C FR 11C0035 I2 FR11C0035 I2 FR 11C0035I2
Authority
FR
France
Prior art keywords
fatty acid
acid esters
aqueous suspensions
hydroxyrisperidone fatty
hydroxyrisperidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0035C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0035(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR11C0035I1 publication Critical patent/FR11C0035I1/fr
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of FR11C0035I2 publication Critical patent/FR11C0035I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
FR11C0035C 1996-05-20 2011-09-02 AQUEOUS SUSPENSIONS OF 9-HYDROXYRISPERIDONE FATTY ACID ESTERS Active FR11C0035I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20
PCT/EP1997/002504 WO1997044039A1 (en) 1996-05-20 1997-05-12 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
EP97923912A EP0904081B1 (en) 1996-05-20 1997-05-12 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Publications (2)

Publication Number Publication Date
FR11C0035I1 FR11C0035I1 (en) 2011-07-10
FR11C0035I2 true FR11C0035I2 (en) 2013-08-16

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0035C Active FR11C0035I2 (en) 1996-05-20 2011-09-02 AQUEOUS SUSPENSIONS OF 9-HYDROXYRISPERIDONE FATTY ACID ESTERS

Country Status (38)

Country Link
US (1) US6077843A (en)
EP (1) EP0904081B1 (en)
JP (1) JP3274687B2 (en)
KR (1) KR100358373B1 (en)
CN (1) CN1093762C (en)
AR (1) AR007194A1 (en)
AT (1) ATE208619T1 (en)
AU (1) AU715572B2 (en)
BG (1) BG62684B1 (en)
BR (1) BR9706824B8 (en)
CA (1) CA2236691C (en)
CY (2) CY2270B1 (en)
CZ (1) CZ291284B6 (en)
DE (2) DE122011100027I1 (en)
DK (1) DK0904081T3 (en)
EA (1) EA000536B1 (en)
EE (1) EE03594B1 (en)
ES (1) ES2167745T3 (en)
FR (1) FR11C0035I2 (en)
HK (1) HK1017852A1 (en)
HR (1) HRP970276B1 (en)
HU (2) HU224025B1 (en)
ID (1) ID16927A (en)
IL (1) IL124551A (en)
LU (1) LU91842I2 (en)
MX (1) MX9804816A (en)
MY (1) MY126302A (en)
NO (2) NO315931B1 (en)
NZ (1) NZ330369A (en)
PL (1) PL188309B1 (en)
PT (1) PT904081E (en)
SI (1) SI0904081T1 (en)
SK (1) SK284013B6 (en)
TR (1) TR199800923T2 (en)
TW (1) TW487572B (en)
UA (1) UA61898C2 (en)
WO (1) WO1997044039A1 (en)
ZA (1) ZA974331B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (en) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form
JP2002504505A (en) * 1998-02-25 2002-02-12 アボット・ラボラトリーズ Butorphanol sustained release formulation
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
ATE313319T1 (en) 1999-03-31 2006-01-15 Janssen Pharmaceutica Nv PREGELATINATED STARCH IN A CONTROLLED RELEASE FORMULATION
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP3751942B2 (en) * 2000-08-14 2006-03-08 テバ ファーマシューティカル インダストリーズ リミティド Preparation of risperidone
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
DE60316454T2 (en) * 2002-07-29 2008-06-26 Alza Corp., Mountain View METHOD AND METHOD OF FORMING THE CONTROLLED DELIVERY OF PALIPERIDONE
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
AU2004285448C1 (en) 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
EP2633853A1 (en) * 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Long-term delivery formulations and methods of use thereof
ES2245252B1 (en) * 2004-06-15 2007-03-01 Farmalider, S.A. RISPERIDONE WATER SOLUTION FOR ORAL ADMINISTRATION.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006114384A1 (en) 2005-04-25 2006-11-02 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
CN102274557B (en) 2006-08-09 2014-12-03 精达制药公司 Osmotic delivery systems and piston assemblies
RU2459824C2 (en) * 2007-04-19 2012-08-27 Юсинь ЛИ New compounds for mental disorders, preparing and using them
DK2157967T3 (en) 2007-04-23 2013-04-08 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and applications thereof
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
AU2008340101B2 (en) 2007-12-19 2015-02-19 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
US20090209757A1 (en) * 2008-01-10 2009-08-20 Santiago Ini Processes for the preparation and purification of paliperidone palmitate
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
MX352189B (en) 2008-09-04 2017-11-10 Amylin Pharmaceuticals Llc Sustained release formulations using non-aqueous carriers.
LT2462246T (en) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
KR20120116401A (en) 2009-10-30 2012-10-22 얀센 파마슈티카 엔.브이. Dosing regimen associated with long-acting injectable paliperidone esters
US20120259116A1 (en) * 2009-12-17 2012-10-11 Rajiv Kumar Novel Process for the Preparation of Paliperidone
TWI577377B (en) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 Pharmaceutical compositions
US9469630B2 (en) 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8940749B2 (en) 2011-05-31 2015-01-27 Ramamohan Rao Davuluri Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydor-9-hydroxy-2-methyl-4H-pyrido[ 1, 2-A]-pyrimidin-4-one(paliperidone) and paliperidone palmitate
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (en) * 2011-09-10 2016-02-03 鲁翠涛 Paliperidone amino-acid ester and preparation method thereof
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RS65024B1 (en) 2015-04-07 2024-01-31 Janssen Pharmaceutica Nv Dosing regimen for missed doses for long-acting injectable paliperidone esters
CN113598842A (en) 2015-06-03 2021-11-05 因塔西亚制药公司 Implant placement and removal system
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
US11666697B2 (en) 2020-11-30 2023-06-06 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
WO2022111860A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
RS65178B1 (en) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
IL303251A (en) 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
HUP2100259A1 (en) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Controlled release injectable cariprazine formulation
AU2022329095A1 (en) 2021-08-20 2024-04-04 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
KR100354270B1 (en) * 1993-11-19 2003-02-11 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazole and 1,2-benzisothiazole
EP2275089A1 (en) * 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Preparation of biodegradable microparticles containing a biologically active agent
JP3122469B2 (en) * 1995-06-06 2001-01-09 ヘキスト・マリオン・ルセル・インコーポレイテツド Pyridineiminyl-1,2-bayisosoxazoles and -benzisothiazoles as antipsychotics
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
HUP9901319A2 (en) 1999-08-30
BG102443A (en) 1999-06-30
TW487572B (en) 2002-05-21
FR11C0035I1 (en) 2011-07-10
JP2000513718A (en) 2000-10-17
HUP9901319A3 (en) 1999-11-29
EE9800136A (en) 1998-10-15
CA2236691C (en) 2007-01-02
PL327995A1 (en) 1999-01-04
ID16927A (en) 1997-11-20
LU91842I2 (en) 2011-09-20
BG62684B1 (en) 2000-05-31
HRP970276B1 (en) 2002-04-30
IL124551A (en) 2001-08-26
EA199800531A1 (en) 1998-12-24
KR100358373B1 (en) 2003-02-11
KR19990067603A (en) 1999-08-25
SI0904081T1 (en) 2002-04-30
DK0904081T3 (en) 2002-02-25
EE03594B1 (en) 2002-02-15
EP0904081A1 (en) 1999-03-31
AU715572B2 (en) 2000-02-03
MY126302A (en) 2006-09-29
EP0904081B1 (en) 2001-11-14
AR007194A1 (en) 1999-10-13
CZ140198A3 (en) 1999-04-14
NO315931B1 (en) 2003-11-17
CZ291284B6 (en) 2003-01-15
AU2955997A (en) 1997-12-09
BR9706824B8 (en) 2015-02-18
PL188309B1 (en) 2005-01-31
PT904081E (en) 2002-04-29
CY2270B1 (en) 2003-07-04
US6077843A (en) 2000-06-20
CA2236691A1 (en) 1997-11-27
CN1206347A (en) 1999-01-27
SK62098A3 (en) 2000-04-10
WO1997044039A1 (en) 1997-11-27
TR199800923T2 (en) 1999-09-21
ES2167745T3 (en) 2002-05-16
JP3274687B2 (en) 2002-04-15
DE122011100027I1 (en) 2011-11-17
NO981984D0 (en) 1998-04-30
HUS1100013I1 (en) 2017-03-28
MX9804816A (en) 1998-10-31
HK1017852A1 (en) 1999-12-03
HRP970276A2 (en) 1998-04-30
EA000536B1 (en) 1999-10-28
DE69708284T2 (en) 2002-07-25
DE69708284D1 (en) 2001-12-20
IL124551A0 (en) 1998-12-06
SK284013B6 (en) 2004-08-03
CY2011011I2 (en) 2016-12-14
BR9706824A (en) 1999-03-23
HU224025B1 (en) 2005-05-30
UA61898C2 (en) 2003-12-15
CN1093762C (en) 2002-11-06
CY2011011I1 (en) 2016-12-14
NZ330369A (en) 2000-04-28
NO2011015I2 (en) 2013-03-11
NO981984L (en) 1998-11-19
ZA974331B (en) 1998-11-19
ATE208619T1 (en) 2001-11-15
NO2011015I1 (en) 2011-09-19

Similar Documents

Publication Publication Date Title
FR11C0035I2 (en) AQUEOUS SUSPENSIONS OF 9-HYDROXYRISPERIDONE FATTY ACID ESTERS
DE69814451D1 (en) AQUEOUS SUSPENSIONS OF SUBMICRON 9-HYDROXYRISPERIDONE FATTY ACID ESTERS
ITPD940043A0 (en) "ACTIVE ESTERS OF CARBOXYLIC POLYSACCHARIDES"
PT823895E (en) ESTERS OF FATTY ACIDS AS COMPOUND BIOACTIVES
DE69624466D1 (en) USE OF ETHOXILIZED FATTY ACID ESTERS AS SELF-SMOOTHING COMPONENTS
PT0900782E (en) ESTER OF 2-CYANACRYLIC ACID
DE69625843D1 (en) Dextrin and fatty acid esters and their use
IL115594A (en) Preparation of alpha-tertiary carboxylic acid esters
FR2782638B1 (en) COSMETIC USE OF FATTY ACIDS
FR2757165B1 (en) ESTER OF MALEIMIDOBENZOIC ACID
IL122919A0 (en) Preparation of 1-alkyl-pyrazole-5-carboxylic acid esters
DE29617590U1 (en) Preparation of phosphoric acid ester